Last updated: 2026-09-28 21:03:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Definium Therapeutics, Inc. (DFTX) operates in the MEDICINAL CHEMICALS & BOTANICAL PRODUCTS sector and is listed on NASDAQ. The stock is currently priced at $38.43, with a market capitalization of $4.86B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.62 to $49.70. This page covers its latest market performance, valuation, price trends and company information.
$4.86B | |
$35.92 | |
$49.70 | |
$14.62 | |
$36.17 | |
2.66M | |
2.23M | |
-- | |
$49.70 | |
$14.62 | |
-- | |
-- |
Definium Therapeutics, Inc. (DFTX) is trading at $38.63 in after-hours trading as of 2026-09-28 21:03:00, up 6.79% ($2.46) from the regular-session close of $36.17.
After-hours trading shows how investors are pricing DFTX after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Definium Therapeutics, Inc. (DFTX) moved from $38.68 to $38.43, representing a decline of 0.66% ($0.25).
The stock traded between $35.68 and $40.39 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 2.35 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 67.9%
DFTX is currently trading at $38.43, placing it 67.9% of the way from its 52-week low of $14.62 to its 52-week high of $49.70. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
| Industry | MEDICINAL CHEMICALS & BOTANICAL PRODUCTS |
| Employees | 106 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Definium Therapeutics, Inc. (DFTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.